Mika Kontro

2.9k total citations
53 papers, 903 citations indexed

About

Mika Kontro is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mika Kontro has authored 53 papers receiving a total of 903 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 23 papers in Molecular Biology and 15 papers in Genetics. Recurrent topics in Mika Kontro's work include Acute Myeloid Leukemia Research (31 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Mika Kontro is often cited by papers focused on Acute Myeloid Leukemia Research (31 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Mika Kontro collaborates with scholars based in Finland, United States and Norway. Mika Kontro's co-authors include Kimmo Porkka, Caroline A. Heckman, Krister Wennerberg, Olli Kallioniemi, Tea Pemovska, Bhagwan Yadav, Muntasir Mamun Majumder, Disha Malani, Tero Aittokallio and Ashwini Kumar and has published in prestigious journals such as Nature, Nature Communications and Blood.

In The Last Decade

Mika Kontro

45 papers receiving 892 citations

Peers

Countries citing papers authored by Mika Kontro

Since Specialization

Citations

This map shows the geographic impact of Mika Kontro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika Kontro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika Kontro more than expected).

Fields of papers citing papers by Mika Kontro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika Kontro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika Kontro. The network helps show where Mika Kontro may publish in the future.

Co-authorship network of co-authors of Mika Kontro

This figure shows the co-authorship network connecting the top 25 collaborators of Mika Kontro. A scholar is included among the top collaborators of Mika Kontro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika Kontro. Mika Kontro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study 2025 ·Blood ·Amer M. Zeidan, Anthony S. Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua F. Zeidner, Emma Searle, (unknown), Petri Bono, (unknown), (unknown), (unknown), Maija Hollmén, Mika Kontro, Naval Daver	1
2	A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia 2025 ·Cancer Research ·Yingjia Chen, Liye He, Aleksandr Ianevski, (unknown), Tanja Ruokoranta, (unknown), Juho J. Miettinen, Markus Vähä‐Koskela, (unknown), Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Anil K. Giri, Tero Aittokallio	4
3	Predictors of response and rational combinations for the novel MCL ‐1 inhibitor MIK665 in acute myeloid leukemia 2025 ·Molecular Oncology ·Joseph Saad, Roland Newman, (unknown), (unknown), Éric Durand, (unknown), Heikki Kuusanmäki, (unknown), Juho J. Miettinen, Komal Kumar Javarappa, (unknown), (unknown), Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman	1
4	Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia 2025 ·npj Digital Medicine ·Y Zhang, (unknown), (unknown), Heikki Kuusanmäki, Frank Emmert‐Streib, (unknown), (unknown), (unknown), Caroline A. Heckman, David L. Gibbs, Vésteinn Thórsson, Ilya Shmulevich, Mika Kontro, Guangrong Qin, (unknown)	0
5	Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 2024 ·Nature Communications ·Aleksandr Ianevski, (unknown), (unknown), Wojciech Senkowski, Daria Bulanova, Lidia Moyano‐Galceran, Tanja Ruokoranta, Heikki Kuusanmäki, (unknown), (unknown), Markus Vähä‐Koskela, Anil K. Giri, Anna Vähärautio, Mika Kontro, Kimmo Porkka, Esa Pitkänen, Caroline A. Heckman, Krister Wennerberg, Tero Aittokallio	13
6	Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine 2024 ·Cell Death and Disease ·(unknown), (unknown), Mette C. Kriegbaum, (unknown), (unknown), Markus Vähä‐Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman	5
7	Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia 2024 ·Blood Advances ·Samuli Eldfors, Joseph Saad, (unknown), Disha Malani, Markus Vähä‐Koskela, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman	3
8	Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window 2024 ·Molecular Cancer Therapeutics ·Tero Satomaa, (unknown), Olli Aitio, Jukka O. Hiltunen, (unknown), Tuula Lähteenmäki, (unknown), Annamari Heiskanen, Anna‐Liisa Hänninen, Ritva Niemelä, Jari Helin, Heikki Kuusanmäki, (unknown), (unknown), Anni I. Nieminen, Emrah Yatkin, Caroline A. Heckman, Mika Kontro, Juhani Saarinen	5
9	Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes 2024 ·Blood ·(unknown), (unknown), Oscar Brück, (unknown), Karita Peltonen, Harri Lähdesmäki, Mika Kontro, Kimmo Porkka, (unknown), Catherine J. Wu, Jani Huuhtanen, Satu Mustjoki	1
10	Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study 2024 ·Blood ·Mika Kontro, Anthony S. Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Jenna H. Rannikko, (unknown), (unknown), (unknown), Birge Berns, (unknown), Inka Pawlitzky, Maija Hollmén, (unknown), Naval Daver	1
11	Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia 2023 ·Leukemia ·(unknown), Taina T. Nieminen, (unknown), (unknown), Mika Kontro, (unknown), Matti Kankainen, Ari Ristimäki, Markus J. Mäkinen, Päivi Lahermo, Caroline A. Heckman, Janna Saarela, Milla Salonen, Anna Lepistö, Heikki Järvinen, Jukka‐Pekka Mecklin, Outi Kilpivaara, Ulla Wartiovaara‐Kautto, Kimmo Porkka, Païvi Peltomäki	1
12	Personalizing precision medicine: Patients with AML perceptions about treatment decisions 2023 ·Patient Education and Counseling ·(unknown), Mika Kontro, (unknown), (unknown), (unknown), Katharina Lang, Chiara Zingaretti, Elena Meggiolaro, Silvia De Padova, Giovanni Marconi, Giovanni Martinelli, Caroline A. Heckman, Giorgia Simonetti, Lars Bullinger, Ulrik Kihlbom	1
13	Abstract A14: Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome 2023 ·Blood Cancer Discovery ·(unknown), (unknown), Heikki Kuusanmäki, Mari Björkman, Juho Jalkanen, Marie-Louise Fjällskog, Caroline A. Heckman, Maija Hollmén, Mika Kontro	1
14	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations 2021 ·Science Advances ·Aleksandr Ianevski, Jenni Lahtela, Komal Kumar Javarappa, (unknown), Bishwa Ghimire, Prson Gautam, Markus Vähä‐Koskela, Laura Turunen, (unknown), Heikki Kuusanmäki, Mika Kontro, Kimmo Porkka, Caroline A. Heckman, Pirkko Mattila, Krister Wennerberg, Anil K. Giri, Tero Aittokallio	27
15	Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS 2021 ·Blood ·Jani Huuhtanen, Oscar Brück, Karita Peltonen, Anna Kreutzman, Olli Dufva, Matti Kankainen, Mette Ilander, Hanna Lähteenmäki, Tiina Kasanen, Jay Klievink, Mika Kontro, Elena J. Orlando, Viviana Cremasco, Joel P. Wagner, Marc R. Pelletier, Harri Lähdesmäki, Catherine Sabatos-Peyton, Mikael L. Rinne, Kimmo Porkka, Satu Mustjoki	1
16	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML 2021 ·Scientific Reports ·(unknown), Disha Malani, Ashwini Kumar, Mika Kontro, Alun Parsons, Olli Kallioniemi, Caroline A. Heckman	9
17	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia 2019 ·Haematologica ·Heikki Kuusanmäki, Aino‐Maija Leppä, Petri Pölönen, Mika Kontro, Olli Dufva, (unknown), Bhagwan Yadav, Oscar Brück, Ashwini Kumar, Hele Everaus, Bjørn Tore Gjertsen, (unknown), Kimmo Porkka, Satu Mustjoki, Caroline A. Heckman	106
18	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia 2016 ·Leukemia ·Samuli Eldfors, Heikki Kuusanmäki, Mika Kontro, Muntasir Mamun Majumder, Alun Parsons, Henrik Edgren, Tea Pemovska, Olli Kallioniemi, Krister Wennerberg, Nicola Gökbuget, Thomas Burmeister, Kimmo Porkka, Caroline A. Heckman	41
19	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia 2016 ·Leukemia ·Mika Kontro, Ashwini Kumar, Muntasir Mamun Majumder, Samuli Eldfors, Alun Parsons, Tea Pemovska, Jani Saarela, Bhagwan Yadav, Disha Malani, Yngvar Fløisand, Martin Höglund, Kari Remes, Bjørn Tore Gjertsen, Olli Kallioniemi, Krister Wennerberg, Caroline A. Heckman, Kimmo Porkka	66
20	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia 2014 ·Oncotarget ·Kati Kämpjärvi, Tiina M. Järvinen, Tuomas Heikkinen, Amy S. Ruppert, Leigha Senter, (unknown), Olli Dufva, Mika Kontro, Laura Z. Rassenti, Erin Hertlein, Thomas J. Kipps, Kimmo Porkka, John C. Byrd, Albert de la Chapelle, Pia Vahteristo	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact